Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Date:11/11/2008

-- First Quarter 2009 Revenue Increased 33.4% to $9.6 Million and Net

Income Increased 10.9% to $1.8 Million -- First Quarter 2009 Gross Margins Improved 1090-Basis Point to 51% over

First Quarter 2008

-- Company Received Chinese SFDA Approval for Fuke Zhidai Tablets

CHENGDU, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced results for its first quarter 2009 ended September 30, 2008.

Revenue for the first quarter of 2009 increased 33.4% to approximately $9.6 million compared to approximately $7.2 million for the first quarter of 2008. The increase in revenues was primarily due to enhanced marketing efforts, expansion of current sales channels and broadened product portfolio.

Cost of goods sold for the first quarter was approximately $4.7 million, yielding a gross profit of $4.9 million and gross margins of 51%, compared to $2.9 million in gross profit and a gross margin of 40.1% during the first quarter of 2008. Thus, gross profits grew by 69.7% on a year-over-year basis. The increase in gross profit and improved margins were primarily attributable to the growth in revenue, the relatively stable price of raw materials and the management's focus on high margin products. The sales of Ginkgo Mihuan Oral Liquid and Arpu Shuangxin, which had comparatively higher gross margin, increased 340% and 31% respectively, compared to that for the same period in 2007.

Operating expenses for the three months ended September 30, 2008 were $2.7 million, up 155.4% compared to the same period in 2007. Selling, g
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
4. Tianyin Pharmaceutical Appoints Three New Independent Board Members
5. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
6. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
7. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
8. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
9. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
11. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... YORK , March 2, 2015 ... scroll to bottom.   Moments ago, Analysts ... including Sunshine Heart (NASDAQ: SSH ), ... ), Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... ). Analysts Review provides a single unified platform for investors, ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... BEIJING , June 29 /PRNewswire-Asia-FirstCall/ -- China ... "Company"), a leading organic,compound fertilizer manufacturer and distributor in ... $10 million as a result of the exercise ... IV, L.P. and CAGP IV,Co-Investment, L.P., two affiliates of ...
... June 29 Reportlinker.com announces that a new market ... , , ... Follow-On Biologics: Global Market Outlook 2010-2025 - opportunities and challenges ... , , ...
... "More than meets the eye" may soon become more ... toys. Researchers at Harvard and MIT have reshaped the ... on the ancient art of origami. Called programmable matter ... composed of interconnected triangular sections could transform itself into a ...
Cached Biology Technology:China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 2China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 3China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 2Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 3Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 5Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 6Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 7Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 8Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 9Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 10Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 11Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 12Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 13Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 14Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 15Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 16Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 17Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 18Shape-shifting sheets automatically fold into multiple shapes 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... to many men during their fight against prostate cancer can ... The findings were published online this week in a pair ... of Sciences . The results may help explain a ... common treatment for men with advanced prostate cancer, generally keeps ...
... Additional Funding by Syncom Venture Partners and Participation ... GE Security, Baker Capital and Lehman Brothers., NEW ... airport,security, has secured $44.4 million in venture funding. Led ... second investor Syncom Venture,Partners, and existing investors Lockheed Martin, ...
... the U.S. Environmental Protection Agency (EPA) announced the award of ... to investigate how the sizes and shapes of nanoparticles affect ... largest EPA Science to Achieve Results (STAR) grant ever awarded ... single grant ever awarded by EPA STAR for nanotechnology research. ...
Cached Biology News:Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: